[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:condition":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100243643","intermountain-inspire-registry-100243643",false,"NCT02450006","Intermountain INSPIRE Registry","INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry)","Inclusion Criteria:\n\n* Males or females of any age, any ethnicity, diagnosed with any healthcare-related conditions, presenting to an Intermountain Healthcare-affiliated facility or males or females of any age, any ethnicity, with or without any healthcare-related conditions, including disease-free subjects, from a general population that may include unaffected family members\n* Patient or patient's representative has the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures, using a form that is approved by the applicable IRB.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally-acceptable representative to provide informed consent for any reason.\n* Other conditions that in the opinion of the Principal Investigator or Co-Investigator(s) may increase risk to the subject and\u002For compromise the quality of the registry project.",true,"ALL",{"count":19,"type":20},50000,"ESTIMATED","50 Years","OBSERVATIONAL","To collect biological samples, clinical information and laboratory data from patients diagnosed with any healthcare-related conditions who are seen at facilities affiliated with Intermountain Healthcare, including patients and their family members, and to collect the same information and samples from a general population including disease-free subjects.",[25],"Condition","RECRUITING","2026-04-09",{"date":29,"type":30},"2026-04-14","ACTUAL",{"date":32,"type":4},"2015-04",{"date":34,"type":20},"2050-04",{"name":36,"class":37},"Intermountain Health Care, Inc.","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100469206","impact-of-cerebellar-tms-on-brain-and-cognitive-functions-in-schizophrenia-a-pilot-study-100469206","NCT05389787","Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study","Inclusion Criteria:\n\n1. Male or female subjects 18 to 60 years of age\n2. DSM-V diagnosis of schizophrenia spectrum disorders\n3. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders\n2. Lifetime diagnosis of ataxia or other cerebellar disorders\n3. Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders\n4. Any active general medical condition or CNS disease which can affect cognition or response to treatment\n5. Substance dependence or abuse in the past six months\n6. Seizure history\n7. TMS within three months or ECT within six months\n8. Pregnancy as indicated by self-report\n9. MRI contraindications","18 Years","60 Years",{"count":48,"type":20},40,"INTERVENTIONAL",[51],"NA","This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:\n\nArm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS\n\nEach participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.",[54,55,25],"Schizophrenia","Cerebellar Function","2025-09-19",{"date":58,"type":30},"2025-09-25",{"date":60,"type":30},"2022-08-18",{"date":62,"type":20},"2027-08-31",{"name":64,"class":37},"Northwell Health"]